Systematic review and network meta ‐analysis comparing ofatumumab with other disease‐modifying therapies available in Japan for the treatment of patients with relapsing multiple sclerosis

ConclusionThese findings, although limited by the paucity of evidence for Japanese patients, suggest that monoclonal antibody therapies (ie, natalizumab and ofatumumab) may provide improved efficacy compared with other DMTs available in Japan for patients with RMS.

Source: Clinical and Experimental Neuroimmunology - July 13, 2022 Category: Neurology Authors: Christopher Drudge, Melody Zhao, Satoru Tanaka, Nozomu Tanaka, Hiromichi Otaka, Izumi Kawachi, Dieter A. H äring, Róisín Brennan, Nicholas Adlard, Imtiaz A. Samjoo Tags: ORIGINAL ARTICLE Source Type: research